Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, has appointed Andrew Satlin, M.D., as executive vice president and chief medical officer.   Dr. Satlin has 20 years of industry experience in all phases of drug development across multiple areas, and most recently was at Eisai, where he spent nine years. He also has experience in the design and conduct of clinical trials in Alzheimer’s disease, Park...